Aarti Drug's Q2FY17 standalone net profit rises 25% yoy to Rs.20 crore : Beats Estimates

India Infoline News Service | Mumbai |

The company’s standalone revenue stood at Rs. 300 crore, up 16.28% yoy and 11.52% qoq.


Standalone Results Q2FY17: (Rs. in crore)

Reported Results YoY (%)
Revenue 300 16.3
EDITDA 50 19.1
EBITDA Margin 16.7% 39 bps
Net Profit (adjusted) 20 25

Technical View:

Aarti Drugs Ltd is currently trading at Rs. 649.2, up by 2.1 points or 0.32% from its previous closing of Rs. 647.1 on the BSE.
The scrip opened at Rs. 655 and has touched a high and low of Rs. 659 and Rs. 645.1 respectively. So far 67445(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 50 DMA.



  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.